https://european-biotechnology.net/wp-content/uploads/2025/08/nathaliemoll-58-copy-e1755857744587.jpg153271Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2025-08-22 10:16:182025-08-22 10:16:18US and EU confirm tariff deal on pharmaceuticals, generics largely exempt
https://european-biotechnology.net/wp-content/uploads/2025/08/mode-of-action-details73-1030x722-1.png7221030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2025-08-21 08:15:042025-08-21 08:15:04Mallia Aesthetics is about to launch MAL-838
https://european-biotechnology.net/wp-content/uploads/2025/08/1656937470420-e1755587656527.jpg451800Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2025-08-19 07:15:482025-08-19 07:15:48BioMed X and Novo Nordisk collaborate to optimise oral peptide therapeutics
https://european-biotechnology.net/wp-content/uploads/2025/08/Lab-31-e1755511169870-1030x580-1.png5801030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2025-08-18 10:02:342025-08-18 10:02:34Anocca raises €38.4m to advance TCR-T leads vs. pancreatic cancer
https://european-biotechnology.net/wp-content/uploads/2025/08/EdiMembre-e1755672266386.png468831Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2025-08-18 06:53:512025-08-18 06:53:51Merck and mantro enter the foodtech market
https://european-biotechnology.net/wp-content/uploads/2025/08/IO-Biotech-ASCO-2025-Cover-Image-e1754920785505-1030x581-1.jpg5811030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2025-08-11 14:00:262025-08-11 19:02:02IO Biotech’s cancer jab falls short in Phase 3, but Danish firm still eyes FDA approval
